Home Newsfeeds MoffettNathanson Downgrades AT&T to Underperform

MoffettNathanson Downgrades AT&T to Underperform

MoffettNathanson analyst Craig Moffett downgrades AT&T (NYSE:T) from Market Perform to Underperform.

byBenzinga Newsdesk

December 19, 2022

1 minute read

MoffettNathanson analyst Craig Moffett downgrades AT&T (NYSE:T) from Market Perform to Underperform.

Estée Lauder, S&P Global, Public Service Enterprise Group And This Leading US Homebuilder Feature On CNBC’s ‘Final Trades’

By Lisa Levin

December 8, 1:35 PM

On CNBC’s "Halftime Report Final Trades," Jim Cramer, the host of the "Mad Money" show, chose The Estée Lauder Companies Inc. (NYSE: EL).

DLocal Stock Surges Into The Close On Earnings Leak, Continues To Climb After Hours: What’s Going On?

By Adam Eckert

August 15, 4:32 PM

DLocal Limited (NASDAQ: DLO) shares soared late Tuesday after the company reported

DLO

The Special Committee Of The Board Of Directors Of Liminal Biosciences Retains An Independent Financial Advisor In Response To Unsolicited Non-Binding Transaction Proposal

By Happy Mohamed

May 8, 8:10 AM

Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), re-confirms that the board of directors of the Company has already established a special committee of the

LMNL

SVB Leerink Initiates Coverage On Vaxcyte with Outperform Rating, Announces Price Target of $60

By Benzinga Newsdesk

December 16, 7:05 AM

SVB Leerink analyst David Risinger initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Outperform rating and announces Price Target of $60.

PCVX

MoffettNathanson Downgrades AT&T to Underperform

Related Posts

Estée Lauder, S&P Global, Public Service Enterprise Group And This Leading US Homebuilder Feature On CNBC’s ‘Final Trades’

DLocal Stock Surges Into The Close On Earnings Leak, Continues To Climb After Hours: What’s Going On?

The Special Committee Of The Board Of Directors Of Liminal Biosciences Retains An Independent Financial Advisor In Response To Unsolicited Non-Binding Transaction Proposal

SVB Leerink Initiates Coverage On Vaxcyte with Outperform Rating, Announces Price Target of $60